Novo Nordisk is increasingly positioning its GLP-1 medications as lifestyle drugs for 'customers' rather than obesity medicines for 'patients,' marking a significant shift in how the company markets these treatments. The change comes as the company continues developing next-generation weight loss drugs and expands its product pipeline.
Brazil's health regulator Anvisa approved five new injectable GLP-1 drugs for diabetes and obesity treatment, following expedited regulatory reviews after Ozempic's patent expired in the country in March 2026.
On July 9, 2026, China's National Health Commission added injectable semaglutide and 115 other drugs to its National Essential Medicines List — the first update in eight years — expanding the catalog to 794 medicines effective September 1, 2026, while domestic oral GLP-1 candidates from Hengrui and Gan & Lee advanced in clinical trials.
A secret shopper investigation of 49 websites prescribing GLP-1 weight loss drugs confirmed experts' concerns about inadequate clinical oversight and fast, easy prescriptions with minimal medical evaluation.
GLP-1 drugs from Pfizer and Innovent Biologics have cleared preliminary review to potentially be included in China's basic medical insurance drug catalogue, which would expand access to these treatments.
New research published in JAMA Otolaryngology analyzing health records from nearly 900,000 patients suggests long-term use of GLP-1 drugs like Ozempic and Mounjaro for diabetes management is associated with increased risks of smell and taste disturbances, though experts note these side effects are not common.
AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.
The Centers for Medicare & Medicaid Services announced that its temporary BALANCE model program to cover GLP-1 drugs for obesity in Medicare will not launch as scheduled in January, effectively extending the current coverage approach.
